BridgeBio Pharma, Inc. (BBIO)
NASDAQ · Healthcare
BridgeBio Pharma, Inc. Long Term Debt 2019–2025
BridgeBio Pharma, Inc. annual/quarterly long term debt history from 2019 to 2025. Long term debt refers to financial obligations that are due more than one year in the future.
- BridgeBio Pharma, Inc. long term debt for the quarter ending December 31, 2025 were 2.01B, a 358.99% increase year-over-year.
- BridgeBio Pharma, Inc. long term debt for 2025 were 2.01B, a 358.99% increase from 2024.
- BridgeBio Pharma, Inc. long term debt for 2024 were 437.3M, a 2.04% decrease from 2023.
- BridgeBio Pharma, Inc. long term debt for 2023 were 446.4M, a 3.59% increase from 2022.
- BridgeBio Pharma, Inc. long term debt for 2022 were 431.0M.
Long Term Debt
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| BridgeBio Pharma, Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2025 | $2,007 |
| 2024 | $437 |
| 2023 | $446 |
| 2022 | $431 |
| 2021 | $431 |
| 2020 | $94 |
| 2019 | $95 |
| BridgeBio Pharma, Inc. Quarterly Long Term Debt (Millions of US $) | |
|---|---|
| 2025-12-31 | $2,007 |
| 2024-12-31 | $437 |
| 2023-12-31 | $446 |
| 2022-12-31 | $431 |
| 2021-12-31 | $431 |
| 2020-12-31 | $94 |
| 2019-12-31 | $95 |
BridgeBio Pharma, Inc. Long Term Debt — FAQ
BridgeBio Pharma, Inc. (BBIO) long term debt over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BBIO's long term debt history?
The chart and table above show BridgeBio Pharma, Inc.'s long term debt by year and by quarter, including the growth rate.